Sponsored Links
BRIEF-Teva Pharm CEO sees 2013 near midpoint of its outlook
Aug 1 (Reuters) - Teva Pharmaceutical Industries Chief Executive Officer said:
* Anticipate to end the year near the midpoint of annual guidance
* Teva previously forecast 2013 revenue of $19.5-$20.5 bln, adjusted EPS of $4.85-$5.15
* Expects 10 NTEs development next 2 years and may start generating sales in 2016
* Sees new therapeutic entities as multi-billion-dollar opportunity
* Prepared with aggressive launch of 3x week Copaxone if approved by FDA in 2014
- Tweet this
- Link this
- Share this
- Digg this
- Reprints



Follow Reuters